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Renal Transplantation in the Presence of a 
Positive Cytotoxic Antibody 
A. Tzakis, T. Hakala, L. Makowka, R. Duquesnoy, R. Gordon, G. Ambrosino, and T.E. Starzl 
W ITH THE EXCEPTION of the B cell 
autoantibodies,' the positive cross-
match is associated with the development of 
hyperacute rejection, and contraindication to 
clinical renal transplantation.2•6 The mere his-
torical presence of cytotoxic antibodi.es, is not 
a contraindication, provided the cross match 
with a current serum (CS) at transplantation 
is negative.7,s In addition the occurrence of 
hyperacute rejection in the presence of a nega-
tive cytotoxic crossmatch,5,9 prompts the ques: 
tion of the limitations of the technique in the 
opposite direction. This report refers to our 
experience with clinical renal transplantation 
in the presence of a doubtful or weakly posi-
tive crossmatch with CS. 
MATERIALS AND METHODS 
Case Material 
A total of 264 cadaveric kidney transplants were 
performed at our institution between December 1984 and 
December 1986. 
Tissue Matching 
Included in this series are 39 patients with a doubtful 
(37) or weakly (2) positive, cytotoxic crossmatch with 
CS. Historical crossmatch was negative in three cases, 
doubtful positive in 24, weakly positive in six, strongly 
positive in five, and not available in one case. 
The presence of preformed, cytotoxic, donor specific, 
antibodies was measured using conventional crossmatch-
ing techniques (Standard Ames Technique). Eighteen of 
the patients were males and 21 females, ranging in age 
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from 16 to 69 years. There were 20 primary and 19 
retransplantations: second graft for 16 patients, third 
graft for two patients, and fifth graft for one patient. 
HLA matching at the HLA A and B loci averaged 
1.38 ± 1.19 SD antigens and at the DR locus 0.56 ± 0.60 
SD antigens (Table I). 
The patients were observed for a period of 2 to 28 
months (average, 11.8 months). 
Immunosuppression 
Cyclosporine A (CsA) was administered orally at a 
dosage of 17.5 mg/kg on admission a few hours before 
transplantation. The treatment was continued postopera-
tively starting with 17.5 mg/kg/d in two divided doses, 
then adjusting the CsA dose according to blood radioim-
munoassay (RIA) levels of CsA. Intravenous (IV) CsA 
was administered when needed. A five-day tapered course 
of steroids, beginning with 200 mg and decreasing by 40 
mg/ d until a maintenance dose of 20 mg/ d was achieved, 
was administered in four divided daily dosages starting on 
the first postoperative day. 
A total of 23 patients were treated with OKT3 (5 mg 
IV bolus daily). In 17 of these patients, the treatment was 
started either intraoperatively or on the first postopera-
tive day. The remaining five required OKT3 treatment 
for rejection episodes at a later time. For five patients, a 
second course of OKT3 was required for treatment of 
rejection episodes. In II patients azathioprine (0.5 to 1.5 
mg/kg/d) was added for various periods of time. 
Rejection episodes were identified by clinical criteria 
(fever, graft tenderness and swelling, oliguria with rising 
serum creatinine) and confirmed by scintigraphy and 
histologic evaluation (Bx), when in doubt. Reversal of 
rejection was characterized by significant fall in serum 
creatinine, restoration of urine output and, in select cases, 
by needle biopsy histology. 
RESULTS 
Mortality 
There were three deaths (7.69%) in this 
series, all due to respiratory failure. The cause 
remains unclear in one patient, a second 
patient died of dissemination of Tuberculosis, 
which was undetected at transplantation and 
the third patient died of H. Influenzae pneu-
moma. 
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Table 1. Immunopathological Data 
Average Average 
Class 1 Class 1 
Match Mismatch 
Average 
Class 2 
Match 
Average 
Class 2 
Mismatch 
Average 
Peak 
PRA 
Average 
Current 
PRA 
Primary transplants 20 1.45 ± .28 2.25 ± 1.26 0.47 ± 0.60 1.0 ± 0.56 34.05 ± 30.6 16.3 ± 25.4 
64.5 ± 31.9 47.4 ± 31.8 Retransplants 19 1.32 ± 1.08 2.47 ± 1.09 0.57 ± 0.62 1.0 ± 0.65 
Total 39 1.38 ± 1.19 2.36 ± 1.19 
Graft Survival 
Twenty eight of 39 patients have life sus-
taining renal function from their transplanted 
graft (average serum creatinine 2.72 mg/dL), 
2 months to 2 years and 4 months after 
transplantation (average 11.18 months), for 
an overall success rate of 71.2%, 80% for 
primary, and 63% for retransplantation (Ta-
ble 2). 
Rejection 
Two patients (5.13%) had hyperacute 
rejection. In one case it was a primary kidney 
allograft while in the other it was a secondary 
kidney transplant. In both cases, the clinical 
observation was confirmed by histologic eval-
uation. The panel-reactive antibody (PRA) 
for the patient receiving the primary trans-
plant was 100% for both historic and current 
sera, and was 10% for both historic and cur-
rent sera in the patient receiving the second-
ary graft. A third patient lost his graft most 
likely due to arterial thrombosis. Four other 
patients (10.26%) lost their grafts to rejection 
at a later date, one occurring in a primary 
transplant and the remaining three following 
kidney retransplantation. 
Primary Non Function 
Four patients in this series had primary 
nonfunction of the graft, two each in the 
0.5 ± 0.60 1.0 ± 0.6 48.9 ± 34.8 31.5 ± 31.89 
primary and secondary transplants, respec-
tively. 
Acute Tubular Necrosis 
Twenty two of these grafts developed acute 
tubular necrosis (ATN), for an overall rate of 
56.41 %: 70% in the primary transplants and 
42% in retransplants. A TN lasted for more 
than a month in six cases. Life sustaining 
renal function could not be maintained for 
more than a few months in two of these 
patients, due to repeated rejection episodes. 
The remaining four patients recovered and are 
stable and dialysis free (average serum creati-
nine 3.2 mg/dL). 
DISCUSSION 
The cytotoxic cross match, since its intro-
duction into clinical practice,6 has defined the 
permissibility of clinical renal transplanta-
tion, with the notable exception of the cases in 
which positivity is due to autoantibodies. 
The feasibility of successful renal trans-
plantation in patients with a historically posi-
tive, but currently (at transplantation) nega-
tive cross match has been shown by both 
Cardella et aP and Kerman et aI.' This report 
refers to a single institutional experience with 
renal transplantation in the face of current 
positive crossmatch, at transplantation. The 
Table 2. Clinical Data 
Hyperacute Primary 
(Rejection) Nonfunction 
Primary Tx 20 2 
ReTx 19 1· 2 
Total 39 2 4 
Abbreviations: Tx, transplantation; ReTx; retransplantation . 
• Additional graft was lost to arterial thrombosis (ReTx'. 
Graft Loss Eventual 
ATN (Rejection) Satisfactory Result 
14 16 
8 3 12 
22 4 28 
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patients in this series belong to a group of 
patients who have repeatedly demonstrated 
positive cross match to a succession of donors, 
and the presence of a doubtful or weakly 
positive cross match was thought to represent 
a unique therapeutic window. 
The results, although somewhat inferior to 
our overall results, can still be considered 
gratifying, in view of the high-risk population 
involved. The high mortality observed in this 
series is probably related to the intense immu-
nosuppression that was required. Additional-
ly, in one case, it was due to failure to re-
cognize pulmonary tuberculosis, predating 
transplantation. 
The ATN incidence in this series (56.41 %) 
is higher than the average (30%) at our cen- -
ter; in six cases, it was unusually long and was 
followed by graft loss due to rejection shortly 
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after recovery in two of these cases. In addi-
tion, the number of cases of primary nonfunc-
tion was higher than in our general transplant 
population. It is our belief, that the above 
discrepancies from our average case load, 
represent unrecognized immunologic reac-
tions and are variations of the observations 
made by Iwaki et al9 on nonfunctioning kid-
neys in immunized patients. 
Based on the data derived from this initial 
clinical experience, it is apparent that success-
ful renal transplantation can be achieved in 
the face of doubtful or weakly positive cross-
match, with results approaching those of the 
general population. Because intense immuno-
therapy is expected to be needed, careful 
patient selection is necessary to avoid unnec-
essary mortality. 
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